524 related articles for article (PubMed ID: 31186274)
21. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A
JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505
[TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.
Allen PB; Savas H; Evens AM; Advani RH; Palmer B; Pro B; Karmali R; Mou E; Bearden J; Dillehay G; Bayer RA; Eisner RM; Chmiel JS; O'Shea K; Gordon LI; Winter JN
Blood; 2021 Mar; 137(10):1318-1326. PubMed ID: 32992341
[TBL] [Abstract][Full Text] [Related]
23. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
Straus DJ; Jung SH; Pitcher B; Kostakoglu L; Grecula JC; Hsi ED; Schöder H; Popplewell LL; Chang JE; Moskowitz CH; Wagner-Johnston N; Leonard JP; Friedberg JW; Kahl BS; Cheson BD; Bartlett NL
Blood; 2018 Sep; 132(10):1013-1021. PubMed ID: 30049811
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
[TBL] [Abstract][Full Text] [Related]
25. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.
Böll B; Goergen H; Behringer K; Bröckelmann PJ; Hitz F; Kerkhoff A; Greil R; von Tresckow B; Eichenauer DA; Bürkle C; Borchmann S; Fuchs M; Diehl V; Engert A; Borchmann P
Blood; 2016 May; 127(18):2189-92. PubMed ID: 26834240
[TBL] [Abstract][Full Text] [Related]
26. Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
Rubinstein PG; Moore PC; Rudek MA; Henry DH; Ramos JC; Ratner L; Reid E; Sharon E; Noy A;
AIDS; 2018 Mar; 32(5):605-611. PubMed ID: 29280762
[TBL] [Abstract][Full Text] [Related]
27. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
28. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.
Johnson P; Federico M; Kirkwood A; Fosså A; Berkahn L; Carella A; d'Amore F; Enblad G; Franceschetto A; Fulham M; Luminari S; O'Doherty M; Patrick P; Roberts T; Sidra G; Stevens L; Smith P; Trotman J; Viney Z; Radford J; Barrington S
N Engl J Med; 2016 Jun; 374(25):2419-29. PubMed ID: 27332902
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review.
Arabloo J; Azari S; Gorji HA; Rezapour A; Alipour V; Ehsanzadeh SJ
Eur J Clin Pharmacol; 2023 Nov; 79(11):1443-1452. PubMed ID: 37656182
[TBL] [Abstract][Full Text] [Related]
30. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
[TBL] [Abstract][Full Text] [Related]
31. Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
Santoro A; Mazza R; Spina M; Califano C; Specchia G; Carella M; Consoli U; Palombi F; Musso M; Pulsoni A; Kovalchuk S; Bonfichi M; Ricci F; Fabbri A; Liberati AM; Rodari M; Giordano L; Chimienti E; Balzarotti M; Sorasio R; Gallamini A; Ghiggi C; Ciammella P; Ricardi U; Chauvie S; Carlo-Stella C; Merli F
Ann Hematol; 2021 Oct; 100(10):2547-2556. PubMed ID: 34327561
[TBL] [Abstract][Full Text] [Related]
32. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma.
Connors JM; Ansell SM; Fanale M; Park SI; Younes A
Blood; 2017 Sep; 130(11):1375-1377. PubMed ID: 28733323
[No Abstract] [Full Text] [Related]
33. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
Ogura M; Itoh K; Ishizawa K; Kobayashi Y; Tobinai K; Kinoshita T; Hirano M; Ueda R; Shibata T; Nakamura S; Tsukasaki K; Hotta T; Shimoyama M; Morishima Y;
Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
[TBL] [Abstract][Full Text] [Related]
34. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).
Ogura M; Itoh K; Kinoshita T; Fukuda H; Takenaka T; Ohtsu T; Kagami Y; Tobinai K; Okamoto M; Asaoku H; Sasaki T; Mikuni C; Hirano M; Chou T; Ohnishi K; Ohno H; Nasu K; Okabe K; Ikeda S; Nakamura S; Hotta T; Shimoyama M
Int J Hematol; 2010 Dec; 92(5):713-24. PubMed ID: 21076995
[TBL] [Abstract][Full Text] [Related]
36. Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States.
Winter A; Liu N; Surinach A; Fanale M; Yu KS; Narkhede M
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):527-534. PubMed ID: 37121857
[TBL] [Abstract][Full Text] [Related]
37. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
38. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
39. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.
Castellino SM; Pei Q; Parsons SK; Hodgson D; McCarten K; Horton T; Cho S; Wu Y; Punnett A; Dave H; Henderson TO; Hoppe BS; Charpentier AM; Keller FG; Kelly KM
N Engl J Med; 2022 Nov; 387(18):1649-1660. PubMed ID: 36322844
[TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
